Novartis, GSK win EU's blessing for big asset swap; Baxter's forecast disappoints; India's Lupin now free to sell up to 49% stake;

@FiercePharma: GSK to divest meningitis shots in exchange for EU clearance of Novartis deal. More from FierceVaccines | Follow @FiercePharma

@EricPFierce: Do you want to know about the newest stents or heart valves approved by the FDA in 2014. Read on. Feature | Follow @EricPFierce

> European regulators approved the big asset swap proposed by Novartis ($NVS) and GlaxoSmithKline ($GSK), a deal designed to refocus the operations of both companies, provided the drugmakers divest several particular products. Report

> Baxter International ($BAX), which is preparing to spin off its biopharma business, reported strong fourth-quarter numbers, but its profits outlook for 2015 disappointed investors. Report

> Thanks to an Indian Cabinet decision, Lupin can now market a minority stake of up to 49% to foreign investors; the previous cap was 33%, and market-watchers figure on a potential capital influx of more than $1 billion. Report

> Two years in the making, a new draft of Pakistan's pricing policy, which would peg prices to those in neighboring India and Bangladesh, is raising hackles in the pharma industry. Report

Medical Device News

@FierceMedDev: ICYMI yesterday: Abiomed shares hit all-time high due to strong demand for its Impella heart pumps. Article | Follow @FierceMedDev

@EmilyWFierce: Gilead zooms past AbbVie in hep C race with UnitedHealth deal. More | Follow @EmilyWFierce

> 2015 med tech IPO kick-off: Entellus exceeds expectations, while Presbia gets the deal done. Article

> China FDA approves Agilent's microarray scanner for in vitro diagnostics. Story

> Philips and Teva unveil new med tech incubator in Israel. Report

Biotech News

@FierceBiotech: AstraZeneca bolts together a top transatlantic team for CRISPR R&D. Report | Follow @FierceBiotech

@JohnCFierce: If you contrast the $NVS approach to CRISPR and $AZN's, $NVS seems much more focused. | Follow @JohnCFierce

@DamianFierce: Christoph Westphal's Flex Pharma prices an $86.4M IPO. News | Follow @DamianFierce

> One big reason why CNS drug development has foundered. More

> Merck KGaA abandons Symphogen's cancer drug ahead of Phase III. Article

> AnaMar rethinks pipeline after analyzing ashes of failed trial. Story

> Karolinska Development CEO leaves 3 months after taking the job. Report

Vaccines News

> Novartis' Bexsero picks up FDA nod--but with competition looming, approval isn't everything. Article

> Pfizer's Prevenar price cut 'inadequate,' critics say. More

> Serum threatens Merck's Gardasil with low-cost competitor. Story

> First batch of GSK/NIH Ebola candidate shipped for Phase III trial in Liberia. Report

> GSK to divest meningitis shots in exchange for EU clearance of Novartis deal. Item

Pharma Manufacturing News

> Chinese Pharmacopoeia venture up and running as safety push continues. More

> AmerisourceBergen again reports big leaps in revenue and earnings. Report

> GSK awards contract for API plant in Scotland. News

> International regulators offer to help India build expertise. Story

> Ranbaxy earnings pulled back down by manufacturing issues. Article

And Finally... Cholesterol-fighting statin drugs may actually benefit women as much as they do men. Report

Suggested Articles

With a brand new approval for Adakveo under its belt, Novartis Sunday flaunted an analysis showing the drug could cut patient hospitalizations by 40%.

BeiGene only just won its first Brukinsa nod in MCL. But it’s already pushing to join the CLL field, and Sunday it rolled out more data.

How long can one infusion of CAR-T drug Yescarta continue helping patients with refractory large B-cell lymphoma? Pretty long, Gilead showed Saturday.